Business
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
JAGX's securities continue to be listed and traded on NasdaqJaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug
About this update from Jaguar Health, Inc.
[{"type":"text","content":"JAGX's securities continue to be listed and traded on NasdaqJaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today announced that on June 25, 2024 the Company received formal notice from The Nasdaq Stock Market LLC (\"Nasdaq\") that Jaguar has regained compliance with Nasdaq's minimum bid price requirement.\"We are very happy that Jaguar has regained compliance with Nasdaq. We consider our Nasdaq listing an asset of the Company,\" said Lisa Conte, Jaguar's president and CEO. \"A Jaguar investor webcast held on or before July 23, 2024 will provide updates on Jaguar's advancing cancer supportive care portfolio, and will include members of Jaguar's scientific team, patient advocates, and leading oncology experts on two of the most common and intolerable side effects of cancer therapy: CTD and oral mucositis.\"About the Jaguar Health Family of CompaniesJaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Crofelemer also is the subject of Napo's phase 3 OnTarget clinical trial for preventive treatment of cancer therapy-related diarrhea (CTD). Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged...